| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/02/2003 | EP1297828A1 Oral formulations for localized colonic release and the method of preparation thereof |
| 04/02/2003 | EP1297827A2 Film forming composition comprising sucralose and carrageenan |
| 04/02/2003 | EP1297826A1 Nasal pharmaceutical compositions containing a NK-2 antagonist |
| 04/02/2003 | EP1297753A1 Flavour-active peptides |
| 04/02/2003 | EP1297169A2 Method for transfecting cells using a magnetic field |
| 04/02/2003 | EP1297142A2 Dual specificity antibodies and methods of making and using |
| 04/02/2003 | EP1297017A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 04/02/2003 | EP1297002A2 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 04/02/2003 | EP1297001A1 Amphipathic linear peptides and compositions containing same |
| 04/02/2003 | EP1296941A2 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants |
| 04/02/2003 | EP1296929A2 Modified forms of pharmacologically active agents and uses therefor |
| 04/02/2003 | EP1296724A1 Bioadhesive composition and methods of preparation and use |
| 04/02/2003 | EP1296719A2 Dextrin - amphotericin conjugates and their methods of preparation |
| 04/02/2003 | EP1296718A1 Pharmaceutical composition of modified pna molecules |
| 04/02/2003 | EP1296717A1 Improvement of itraconazole bioavailability |
| 04/02/2003 | EP1296709A1 Solubilised protein vaccines |
| 04/02/2003 | EP1296705A1 Neurotoxic oligomers |
| 04/02/2003 | EP1296702A1 Neuroprotective peptides |
| 04/02/2003 | EP1296699A1 Therapeutic agents - iii |
| 04/02/2003 | EP1296698A1 Therapeutic agents - ii |
| 04/02/2003 | EP1296697A1 Therapeutic agents - i |
| 04/02/2003 | EP1296691A2 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections |
| 04/02/2003 | EP1296685A1 Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| 04/02/2003 | EP1296678A2 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 04/02/2003 | EP1296676A1 Use of indole-3-acetic acid derivatives in medicine |
| 04/02/2003 | EP1296673A1 Antimicrobial coatings |
| 04/02/2003 | EP1296672A1 Stable pharmaceutical product and formulation |
| 04/02/2003 | EP1296666A2 Improved thyroid hormone formulations |
| 04/02/2003 | EP1296664A2 Propofol for treatment of sepsis |
| 04/02/2003 | EP1296661A2 Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities |
| 04/02/2003 | EP1296660A1 The controlled release preparation of insulin and its method |
| 04/02/2003 | EP1296659A1 Pharmaceutical compositions of 2'-deoxy-2'-(fluoromethylene)cytidine |
| 04/02/2003 | EP1296658A1 Use of an acetylated pre-gelled starch with a high content of amylose |
| 04/02/2003 | EP1296657A1 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
| 04/02/2003 | EP1296656A2 Method for preparing a composition |
| 04/02/2003 | EP1296655A1 Endoparasiticidal agents for voluntary oral ingestion by animals |
| 04/02/2003 | EP1296653A1 Method for formulating healthcare products with enhanced stability |
| 04/02/2003 | EP1296652A1 Topical pharmaceutical formulations and methods of treatment |
| 04/02/2003 | EP1296651A1 Method of making particles for use in a pharmaceutical composition |
| 04/02/2003 | EP1296650A2 Methods and compositions for treating pain of the mucous membrane |
| 04/02/2003 | EP1296648A1 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/02/2003 | EP1296647A2 Polymeric micelle compositions |
| 04/02/2003 | EP1296645A2 Methods for treating inflammation-mediated conditions of the eye |
| 04/02/2003 | EP1296644A2 Systems and methods for treating a mucosal surface |
| 04/02/2003 | EP1246627A4 Polyanhydrides with biologically active degradation products |
| 04/02/2003 | EP1211942B1 Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution |
| 04/02/2003 | EP1191999B1 Method of particle formation |
| 04/02/2003 | EP1140479B1 Apparatus and method for manufacturing moulded products |
| 04/02/2003 | EP1107739B1 Method for producing solid dosing forms |
| 04/02/2003 | EP1045863B1 Detoxication of active pharmaceutical substances using cyclodextrine oligomers |
| 04/02/2003 | EP1001732B1 Shellac-containing cosmetic product |
| 04/02/2003 | EP0952822B1 Chitosan-gelatin a microparticles |
| 04/02/2003 | EP0946624B1 Biodegradable targetable microparticle delivery system |
| 04/02/2003 | EP0946146B1 Use of aqueous medicament preparations for the production of propellent gas-free aerosols |
| 04/02/2003 | EP0927053B1 Fragmented polymeric hydrogels for adhesion prevention and their preparation |
| 04/02/2003 | EP0917458B1 Lyophilized thioxanthenone antimumor agents |
| 04/02/2003 | EP0914460B1 Vehicle for the transport of molecular substances |
| 04/02/2003 | EP0910348B1 Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof |
| 04/02/2003 | EP0885189B9 Method for the synthesis of poly-pyrrole and poly-imidazole carboxamides on a solid support |
| 04/02/2003 | EP0830380B1 Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2, 5-anhydro-d-mannose terminal structure and conjugate vaccine thereof |
| 04/02/2003 | EP0828481B1 Oral dosage composition comprising zonula occludens toxin and a biologically active ingredient and use thereof |
| 04/02/2003 | EP0804283B1 Aqueous solvent encapsulation method and microcapsules |
| 04/02/2003 | EP0762897B1 Method of preventing aggregation of proteins/peptides upon rehydration or thawing |
| 04/02/2003 | EP0737066B1 Transdermal device containing polyvinylpyrrolidone as solubility enhancer |
| 04/02/2003 | EP0700444B1 Immunotoxins comprising gelonin and an antibody |
| 04/02/2003 | CN1408004A Water unstable foam |
| 04/02/2003 | CN1407978A Polyhydroxystilbenes and stibene oxides as antisoriatic agents and protein kinase inhibitors |
| 04/02/2003 | CN1407898A Novel topical oestroprogestational compositions with systemic effect |
| 04/02/2003 | CN1407888A Film preparation for biphasic release of pharmacologically active or other substances |
| 04/02/2003 | CN1407887A Oral liquid compositions |
| 04/02/2003 | CN1407886A Multi-layer preparation in film form, consisting of hydrophilic polymers, for rapid release of active ingredients |
| 04/02/2003 | CN1407885A Histamine H2 antagonist effervescent composition |
| 04/02/2003 | CN1406634A Medical adhesive composition, adhesive tape therefrom and endermic absorbed adhesive tape products |
| 04/02/2003 | CN1406587A Use of activated carbon in oral medicinal preparation for hyperthyroidism |
| 04/02/2003 | CN1406584A Gel composition for killing parasites |
| 04/02/2003 | CN1104501C Modified human C3 proteins |
| 04/02/2003 | CN1104258C Excipient for difficult soluble medicine |
| 04/02/2003 | CN1104256C Cyclosporin soft capsule composition |
| 04/02/2003 | CN1104240C Composition comprising amoxycillin and clavulanic acid, its preparation and use |
| 04/02/2003 | CN1104237C Use of omega-3 polyunsaturated acids |
| 04/02/2003 | CN1104234C Carotenoid preparation capable of mixing with liquid and oil |
| 04/01/2003 | US6541669 Multibinding amine compounds which are beta 2 adrenergic receptor agonists useful in treatment and prevention of respiratory diseases such as asthma, bronchitis |
| 04/01/2003 | US6541629 Enzyme inhibitors |
| 04/01/2003 | US6541612 Complex of rapamycin-42 ester with dicarboxylic acid and fluorescein; antibody detection/generation; immunoglobulins; hybridomas; ring opening; precipitation |
| 04/01/2003 | US6541606 Stabilized protein crystals formulations containing them and methods of making them |
| 04/01/2003 | US6541543 An activated, water soluble polymer comprising a polymer backbone having at least one terminus bonded to a branching atom through a hydrolytically stable linkage, and branching atom being covalently bonded to atleast two reactive groups |
| 04/01/2003 | US6541523 Methods for treating or preventing fibromyalgia using very low doses of cyclobenzaprine |
| 04/01/2003 | US6541518 Preventing pathogens in blood plasma and for enhancing the production of cryoprecipitate from plasma by adding a low molecular weight carboxylic acid or salt to the plasma, preferably trisodium citrate |
| 04/01/2003 | US6541508 Water solubility; prodrug containing polyether oligomer |
| 04/01/2003 | US6541462 Sphingomyelin enhancement of tumor therapy |
| 04/01/2003 | US6541447 Wound healing composition and method for use thereof |
| 04/01/2003 | US6541225 Methods and compositions for generating human monoclonal antibodies |
| 04/01/2003 | US6541224 Protein for use in treatment, diagnosis and prevention of autoimmune disease |
| 04/01/2003 | US6541212 Anticancer agents |
| 04/01/2003 | US6541040 Mixture consists of paraffins or synthetic waxes selected from montan waxes, petroleum waxes, Fischer-Tropsch waxes, polyolefin waxes, petrolatum waxes, wax alcohol and oxidates and atleast one alkali or alkaline hydroxide |
| 04/01/2003 | US6541033 Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| 04/01/2003 | US6541030 Subjectign aqueous mixture of a water insoluble core material, a water soluble glucopyranosidyl material, and an emulsifying formulation to a pressure force to form an aqueous micro-emulsion, and removing water to form microcapsules |
| 04/01/2003 | US6541025 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| 04/01/2003 | US6541021 Completely implanting in a patient, at a implntation site, a controlled release drug delivery device containing a pump and a drug selected from fentanyl and a fetanyl congener, such as sufentanil for treating the pain for atleast about 3-days |
| 04/01/2003 | US6541020 An antiviral agent consists of a polymer material that forms a hydrogel at physiological temperatures, and a polypeptide having a specific amino acid sequence |